Monoclonal Antibody
Rocheās Ocrevus shows similar efficacy and safety in subcutaneous and intravenous forms
Roche’s innovative subcutaneous adaptation of its highly-regarded multiple sclerosis (MS) medication, Ocrevus, has achieved a significant breakthrough in a pivotal ...
GSKās Nucala Gets Closer to Approval for Severe Asthma in Japan
GSK has unveiled a ray of hope for millions of Japanese individuals grappling with the debilitating burden of chronic rhinosinusitis ...
Magrolimab for myelodysplastic syndromes is discontinued by Gilead
Source – Gilead Science Gilead Sciences has announced the discontinuation of its cancer antibody, magrolimab, in the treatment of blood ...
Darzalex Continues Rising Trend – J&J Boosts Projected Yearly Revenues by $1 Billion
In 2017, Genmab CEO Jan van de Winkel envisioned that the multiple myeloma drug Darzalex, marketed by Johnson & Johnson, ...
Lilly’s Acquisition of Versanis Aims to Enhance Patient Outcomes in Cardiometabolic Diseases
Source – Eli Lilly Eli Lilly and Versanis Bio have reached a definitive agreement for Lilly to acquire Versanis, a ...
Promising Phase IIb Results in Atopic Dermatitis: amlitelimab as a Groundbreaking Treatment
Source – Sanofi On June 27, 2023, Sanofi announced positive Phase IIb Results. Amlitelimab shows promise as a first-in-class investigational ...
